Severe Acute Respiratory Syndrome Spike (CT) Blocking Peptide

Severe Acute Respiratory Syndrome Spike (CT) Blocking Peptide

Product No.: S549

[product_table name="All Top" skus="S549"]

- -
- -
SARS Spike
Product Type
Blocking Peptide

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Product Concentration
0.2 mg/ml
Amino Acid Location
20 Amino acids near the C-terminus of SARS Spike protein.
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
Next Day Ambient
Amino Acid Sequence
20 amino acids near the carboxy terminus of SARS Spike protein.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Severe Acute Respiratory Syndrome Spike Protein peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

References & Citations

1. Edwards SW, Derouet M, Howse M, et al. Regulation of neutrophil apoptosis by Mcl-1. Biochem Soc Trans. 2004; 32:489-92. 2. Cuconati A, Mukherjee C, Perez D, et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes and Dev. 2003; 17:2922-32. 3. Opferman JT, Letai A, Beard C, et al. Development and maintenance of B and T lymphocytes require antiapoptotic MCL-1. Nature 2003; 426:671-6. 4. Kozopas KM, Yang T, Buchan HL, et al. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA 1993; 90:3516-20.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.